Credit Suisse Group Reiterates “Buy” Rating for INC Research (INCR)

Credit Suisse Group restated their buy rating on shares of INC Research (NASDAQ:INCR) in a research report released on Thursday. The firm currently has a $52.00 price target on the stock.

A number of other equities research analysts have also recently commented on INCR. KeyCorp restated a buy rating and issued a $50.00 price target on shares of INC Research in a report on Thursday. Zacks Investment Research cut shares of INC Research from a buy rating to a hold rating in a report on Wednesday, October 4th. BidaskClub upgraded shares of INC Research from a hold rating to a buy rating in a report on Wednesday. Mizuho began coverage on shares of INC Research in a report on Thursday, September 21st. They issued a neutral rating and a $57.00 price target for the company. Finally, Jefferies Group upgraded shares of INC Research from a hold rating to a buy rating and raised their price target for the stock from $62.50 to $69.00 in a report on Monday, October 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. INC Research presently has an average rating of Buy and a consensus price target of $50.78.

INC Research (NASDAQ INCR) traded down $0.80 on Thursday, hitting $40.50. 1,480,000 shares of the stock traded hands, compared to its average volume of 1,327,349. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.27 and a current ratio of 1.27. The firm has a market capitalization of $4,225.97, a PE ratio of -69.83, a PEG ratio of 1.25 and a beta of 1.09. INC Research has a 52 week low of $33.60 and a 52 week high of $61.10.

INC Research (NASDAQ:INCR) last posted its quarterly earnings results on Thursday, November 9th. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.09). The company had revenue of $592.21 million during the quarter, compared to analyst estimates of $604.95 million. INC Research had a positive return on equity of 14.42% and a negative net margin of 4.29%. The company’s revenue for the quarter was up 128.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 earnings per share. equities research analysts anticipate that INC Research will post 2.15 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in INCR. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of INC Research by 14.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,765 shares of the company’s stock valued at $103,000 after buying an additional 228 shares in the last quarter. Pacad Investment Ltd. bought a new position in shares of INC Research in the second quarter valued at $123,000. Riverhead Capital Management LLC bought a new position in shares of INC Research in the second quarter valued at $128,000. Victory Capital Management Inc. lifted its stake in shares of INC Research by 17.6% in the second quarter. Victory Capital Management Inc. now owns 2,377 shares of the company’s stock valued at $139,000 after buying an additional 356 shares in the last quarter. Finally, Personal Capital Advisors Corp bought a new position in shares of INC Research in the third quarter valued at $234,000. 99.50% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/07/credit-suisse-group-reiterates-buy-rating-for-inc-research-incr.html.

INC Research Company Profile

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Analyst Recommendations for INC Research (NASDAQ:INCR)

What are top analysts saying about INC Research? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for INC Research and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit